Chordate Medical's CEO Anders Weilandt will participate on BioStock Life Science Spring Summit on June 8th, at 11:20. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the United States, the upcoming representative office in Saudi Arabia and the marketing efforts in the United Kingdom.
"Biostocks Life Science Summit events is an important platform for Nordic innovation companies such as Chordate. I look forward to talking about what we have done so far in 2022 and what we have planned for the rest of the year and beyond," says Anders Weilandt, Chordate CEO.
BioStock Life Science Spring Summit will be livestreamed at Biostocks Youtube channel:
Read more about the event: https://www.biostock.se/en/2022/04/biostock-life-science-spring-summit-june-8-9/
For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medicals share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, email@example.com.